Undersøgelse af ITI-1284 som monoterapibehandling hos patienter med generaliseret angstlidelse
En multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til vurdering af effektiviteten, sikkerheden og tolerabiliteten af ITI-1284 som en supplerende behandling hos patienter med generaliseret angstlidelse, som har en utilstrækkelig respons på behandling af generaliseret angstlidelse
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Blagoevgrad, Bulgarien, 2700
- Rekruttering
- Medical Center Sv Dimitar Blagoevgrad
-
Kardzhali, Bulgarien, 6600
- Rekruttering
- Medical Center Lifemed
-
Pleven, Bulgarien, 5800
- Rekruttering
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarien, 4004
- Rekruttering
- Medical Center Mentalcare OOD
-
Rousse, Bulgarien, 7003
- Rekruttering
- Mental Health Center - Rousse
-
Sofia, Bulgarien, 1680
- Rekruttering
- Medical Center Intermedica, OOD
-
Sofia, Bulgarien, 1408
- Rekruttering
- DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
-
Sofia, Bulgarien, 1510
- Rekruttering
- Medical Center Hera EOOD
-
Targovishte, Bulgarien, 7700
- Rekruttering
- Medical center - VAS OOD
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama at Birmingham
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Rekruttering
- Woodland International Research Group
-
Rogers, Arkansas, Forenede Stater, 72758
- Rekruttering
- Woodland Research Northwest
-
-
California
-
Culver City, California, Forenede Stater, 90230
- Rekruttering
- Proscience Research Group
-
Encino, California, Forenede Stater, 91316
- Rekruttering
- Wake Research PRI Encino
-
Encino, California, Forenede Stater, 91316
- Rekruttering
- Leading Edge Research
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- CalNeuro Research
-
Oceanside, California, Forenede Stater, 92056
- Rekruttering
- Excell Research Inc
-
Sherman Oaks, California, Forenede Stater, 91403
- Rekruttering
- California Neuroscience Research
-
Upland, California, Forenede Stater, 91786
- Afsluttet
- Pacific Clinical Research Medical Group
-
Walnut Creek, California, Forenede Stater, 94596
- Rekruttering
- Sunwise Clinical Research
-
-
Connecticut
-
Farmington, Connecticut, Forenede Stater, 06032
- Rekruttering
- University of Connecticut Health Center
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32607
- Afsluttet
- Sarkis Clinical Trials
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Miami Dade Medical Research Institute
-
Tampa, Florida, Forenede Stater, 33613
- Rekruttering
- University of South Florida
-
-
Georgia
-
Decatur, Georgia, Forenede Stater, 30030
- Rekruttering
- iResearch Atlanta LLC
-
-
Mississippi
-
Flowood, Mississippi, Forenede Stater, 39232
- Rekruttering
- Precise Clinical Research, Inc.
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11235
- Rekruttering
- SPRI Clinical Trials, LLC
-
Buffalo, New York, Forenede Stater, 14215
- Rekruttering
- University of Buffalo
-
Staten Island, New York, Forenede Stater, 10314
- Rekruttering
- Richmond Behavioral Associates
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University
-
-
Oklahoma
-
Norman, Oklahoma, Forenede Stater, 73071
- Rekruttering
- Sooner Clinical Research
-
-
Pennsylvania
-
Media, Pennsylvania, Forenede Stater, 19063
- Rekruttering
- Suburban Research Associates
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75243
- Rekruttering
- Relaro Medical Trials
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98007
- Rekruttering
- Northwest Clinical Research Center
-
-
-
-
-
Bialystok, Polen, 15272
- Rekruttering
- Prywatne Gabinety Lekarskie PROMEDICUS
-
Bydgoszcz, Polen, 85-080
- Rekruttering
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polen, 80 283
- Rekruttering
- Centrum Zdrowia Alcea
-
Leszno, Polen, 64-100
- Rekruttering
- Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
-
Torun, Polen, 87 100
- Rekruttering
- Agnieszka Nowakowska Rudzka Gabinet Lekarski TCP Neuromed
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekruttering
- University Clinical Center of Serbia
-
Belgrade, Serbien, 11000
- Rekruttering
- Institute of Mental Health Serbia
-
Belgrade, Serbien, 11000
- Rekruttering
- Clinical Center Dr Dragisa Misovic Dedinje
-
Belgrade, Serbien, 11000
- Rekruttering
- University Clinical Center of Serbia 1
-
Kovin, Serbien, 26220
- Rekruttering
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbien, 34000
- Rekruttering
- University Clinical Center Kragujevac
-
Niš, Serbien, 18000
- Rekruttering
- University Clinical Center NIS
-
Novi Kneževac, Serbien, 23330
- Rekruttering
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Bratislava, Slovakiet, 821 01
- Rekruttering
- Psychiatricka Ambulancia Mentum S.R.O.
-
Rimavská Sobota, Slovakiet, 979 01
- Rekruttering
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Svidník, Slovakiet, 08901
- Rekruttering
- Centrum Zdravia R.B.K. S.R.O. Poliklinika Medic Sk
-
Vranov nad Topľou, Slovakiet, 093 01
- Rekruttering
- Crystal Comfort s.r.o.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Provide written informed consent before the initiation of any study specific procedures;
-
At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD (current GAD) as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:
- HAM-A Total score of ≥ 22;
- HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;
- CGI-S score of ≥ 4;
-
History of inadequate response (< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire [ATRQ] for GAD) to at least 2 of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 milligram [mg], venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and duration (ie, for at least 6 weeks prior to Screening) for the treatment of ongoing GAD symptoms.
Exclusion Criteria:
-
Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
MADRS total score > 18 at Screening or Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;
- At Screening or Baseline MADRS Item 10 score ≥ 5; or
- The patient is considered to be an imminent danger to him/herself or others based on the assessment of the Investigator;
-
Lifetime history of failure to respond to > 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and for an adequate duration (ie, at least 6 weeks)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ITI-1284 10mg
ITI-1284 10 mg tablet, taken once daily, sublingual administration. |
ITI-1284 10 mg tablet, taken once daily, sublingual administration. |
|
Eksperimentel: ITI-1284 20mg
ITI-1284 20 mg tablet, taken once daily, sublingual administration. |
ITI-1284 20 mg tablet, taken once daily, sublingual administration. |
|
Placebo komparator: Placebo
Matching placebo tablet, taken once daily, sublingual administration |
Matching placebo tablet, taken once daily, sublingual administration |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Week 6
|
The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It is comprised of 14 items that are rated on a 5-point scale ranging from 0 = not present to 4 = very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 with a higher score indicating increased severity of anxiety symptoms. |
Week 6
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Global Impression Scale-Severity (CGI-S)
Tidsramme: Week 6
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients) |
Week 6
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Intra-Cellular Therapies,Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ITI-1284-302
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .